Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • GS-1878 evaluated the efficacy and safety of switching virologically suppressed HIV-infected adult patients from a multitablet regimen containing a boosted PI to fixed-dose bictegravir/emtricitabine/tenofovir AF[Daar 2018]
    • Switch to bictegravir/emtricitabine/tenofovir AF was found to be noninferior to continuing a boosted PI–containing regimen and demonstrated no treatment-emergent resistance at 48 weeks

Action required